Liposomal formulations for lung cancer treatment in the last two decades: a systematic review

Detalhes bibliográficos
Autor(a) principal: Canão, Filipa
Data de Publicação: 2022
Outros Autores: Ferreira, Helena, Neves, N. M.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://hdl.handle.net/1822/79332
Resumo: Purpose Lung cancer is the leading cause of cancer mortality worldwide. To improve the therapeutic outcomes, drug delivery systems, and particularly liposomes, have been widely investigated. Therefore, this review analyzed systematically the literature to inquire about the safety and efcacy of liposomal formulations in lung cancer treatment. Methods Three electronic databases (PubMed, Web of Science and Cochrane CENTRAL) were systematically searched until May 2020. Clinical trials containing information about the efects of liposomal formulations in lung cancer patients were considered eligible. Results Twenty two selected studies present diferent treatment options for both small and non-small-cell lung cancers. After compiling and analyzing all the published information, we verifed that combination of liposomal cisplatin and paclitaxel led to a statistically signifcant improvement of the evaluated outcomes. Moreover, tecemotide, a liposome-based immunotherapy, demonstrated lower toxicity compared to control groups. Evidences that other subgroups could beneft from this formulation were also provided. Conclusion This systematic review (registration number CRD42021246587) demonstrates that liposomal formulations are promising alternatives to overcome limitations of traditional cancer therapy. However, larger, longer, randomized and double-blinded clinical trials, selecting their patientsâ cohort considering more responsive subgroups would be benefcial to strengthen the scientifc and clinical evidence of the results herein reported.
id RCAP_ce316c9030ad6c4d4dc825f839b7cf7b
oai_identifier_str oai:repositorium.sdum.uminho.pt:1822/79332
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Liposomal formulations for lung cancer treatment in the last two decades: a systematic reviewAdverse eventsClinical trialsDrug deliveryEfficacyLiposomal formulationsLung cancerScience & TechnologyPurpose Lung cancer is the leading cause of cancer mortality worldwide. To improve the therapeutic outcomes, drug delivery systems, and particularly liposomes, have been widely investigated. Therefore, this review analyzed systematically the literature to inquire about the safety and efcacy of liposomal formulations in lung cancer treatment. Methods Three electronic databases (PubMed, Web of Science and Cochrane CENTRAL) were systematically searched until May 2020. Clinical trials containing information about the efects of liposomal formulations in lung cancer patients were considered eligible. Results Twenty two selected studies present diferent treatment options for both small and non-small-cell lung cancers. After compiling and analyzing all the published information, we verifed that combination of liposomal cisplatin and paclitaxel led to a statistically signifcant improvement of the evaluated outcomes. Moreover, tecemotide, a liposome-based immunotherapy, demonstrated lower toxicity compared to control groups. Evidences that other subgroups could beneft from this formulation were also provided. Conclusion This systematic review (registration number CRD42021246587) demonstrates that liposomal formulations are promising alternatives to overcome limitations of traditional cancer therapy. However, larger, longer, randomized and double-blinded clinical trials, selecting their patientsâ cohort considering more responsive subgroups would be benefcial to strengthen the scientifc and clinical evidence of the results herein reported.SpringerUniversidade do MinhoCanão, FilipaFerreira, HelenaNeves, N. M.2022-062022-06-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/1822/79332engCanão F., Ferreira H., Neves N. M. Liposomal formulations for lung cancer treatment in the last two decades: a systematic review, Journal of Cancer Research and Clinical Oncology , Vol. 148, pp. 2375-2386, doi:10.1007/s00432-022-04079-x, 20221432-133510.1007/s00432-022-04079-x35660950https://doi.org/10.1007/s00432-022-04079-xinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-21T12:30:29Zoai:repositorium.sdum.uminho.pt:1822/79332Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T19:25:40.843191Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Liposomal formulations for lung cancer treatment in the last two decades: a systematic review
title Liposomal formulations for lung cancer treatment in the last two decades: a systematic review
spellingShingle Liposomal formulations for lung cancer treatment in the last two decades: a systematic review
Canão, Filipa
Adverse events
Clinical trials
Drug delivery
Efficacy
Liposomal formulations
Lung cancer
Science & Technology
title_short Liposomal formulations for lung cancer treatment in the last two decades: a systematic review
title_full Liposomal formulations for lung cancer treatment in the last two decades: a systematic review
title_fullStr Liposomal formulations for lung cancer treatment in the last two decades: a systematic review
title_full_unstemmed Liposomal formulations for lung cancer treatment in the last two decades: a systematic review
title_sort Liposomal formulations for lung cancer treatment in the last two decades: a systematic review
author Canão, Filipa
author_facet Canão, Filipa
Ferreira, Helena
Neves, N. M.
author_role author
author2 Ferreira, Helena
Neves, N. M.
author2_role author
author
dc.contributor.none.fl_str_mv Universidade do Minho
dc.contributor.author.fl_str_mv Canão, Filipa
Ferreira, Helena
Neves, N. M.
dc.subject.por.fl_str_mv Adverse events
Clinical trials
Drug delivery
Efficacy
Liposomal formulations
Lung cancer
Science & Technology
topic Adverse events
Clinical trials
Drug delivery
Efficacy
Liposomal formulations
Lung cancer
Science & Technology
description Purpose Lung cancer is the leading cause of cancer mortality worldwide. To improve the therapeutic outcomes, drug delivery systems, and particularly liposomes, have been widely investigated. Therefore, this review analyzed systematically the literature to inquire about the safety and efcacy of liposomal formulations in lung cancer treatment. Methods Three electronic databases (PubMed, Web of Science and Cochrane CENTRAL) were systematically searched until May 2020. Clinical trials containing information about the efects of liposomal formulations in lung cancer patients were considered eligible. Results Twenty two selected studies present diferent treatment options for both small and non-small-cell lung cancers. After compiling and analyzing all the published information, we verifed that combination of liposomal cisplatin and paclitaxel led to a statistically signifcant improvement of the evaluated outcomes. Moreover, tecemotide, a liposome-based immunotherapy, demonstrated lower toxicity compared to control groups. Evidences that other subgroups could beneft from this formulation were also provided. Conclusion This systematic review (registration number CRD42021246587) demonstrates that liposomal formulations are promising alternatives to overcome limitations of traditional cancer therapy. However, larger, longer, randomized and double-blinded clinical trials, selecting their patientsâ cohort considering more responsive subgroups would be benefcial to strengthen the scientifc and clinical evidence of the results herein reported.
publishDate 2022
dc.date.none.fl_str_mv 2022-06
2022-06-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://hdl.handle.net/1822/79332
url https://hdl.handle.net/1822/79332
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Canão F., Ferreira H., Neves N. M. Liposomal formulations for lung cancer treatment in the last two decades: a systematic review, Journal of Cancer Research and Clinical Oncology , Vol. 148, pp. 2375-2386, doi:10.1007/s00432-022-04079-x, 2022
1432-1335
10.1007/s00432-022-04079-x
35660950
https://doi.org/10.1007/s00432-022-04079-x
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799132742038847488